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Sir
We read with great interest the letter of O’Byrne and colleagues.
They confirm previous observations on the relation between
platelet count and serum vascular endothelial growth factor
(VEGF) and on the predictive value of increased serum VEGF and
poor outcome (Dirix et al, 1996, 1997; Salven et al, 1997). These
data also suggest that platelets might be considered as mediators of
VEGF induced tumour-angiogenesis, and thus influence tumour
growth (Pinedo et al, 1998).
In a recent study we have examined the VEGF load in platelets
(VEGFPLT) from 25 healthy volunteers, 30 previously untreated
patients with operable breast cancer and 70 patients with advanced
breast cancer. The healthy volunteers had a VEGF load of 
0.41 pg 10–6 platelets, which gradually increased to 1.00 pg 10–6
platelets for the non-metastatic group to 1.58 pg 10–6 platelets 
for the advanced group (Kruskal–Wallis test, P < 0.0001).
We have previously suggested that interleukin-6 (IL-6) might be
particularly important in tumour-related angiogenesis (Salgado et
al, 1999). Preliminary data derived from the same three subsets of
patients confirm these data, showing a significant correlation
between circulating levels of IL-6 and the VEGFPLT in the group
with advanced breast cancer (Spearman rank test, P < 0.002). A
significant difference was also observed between mean IL-6 levels
in the control vs locoregional disease group (0.5 pg ml–1 vs 1.4 pg
ml–1 respectively, Mann–Whitney U-test, P = 0.041) and between
these and the advanced group (1.4 pg ml–1 vs 12.4 pg ml–1 respec-
tively, Mann–Whitney U-test, P < 0.0001).
In a second study we measured serum IL-6 levels in the effluent
mesenteric vein in seven patients suffering from an operable
colorectal carcinoma and compared these values with those
obtained from an arterial (art.) and peripheral venous (pv.) blood
sample. Arterial and peripheral venous IL-6 did not reach the
detection limit of the assay (3.1 pg ml–1) in 75% and 63% of the
patients respectively (means of 2.2 pg ml–1 and 2.5 pg ml–1 respec-
tively), whereas 88% of the patients had high (> 3.1 pg ml–1)
venous mesenteric IL-6 levels (mean 15.7 pg ml–1; Fisher exact
test between art. vs vm. values, P = 0.04). Remarkably, in three
other patients known to have disseminated disease, 67% had both
peripheral venous and arterial IL-6 values (means of 7.7 pg ml–1
and 7.22 pg ml–1 respectively) higher than the detection limit. All
the patients had high mesenteric venous values (mean 38 pg ml–1,
Fisher exact test between art./pv vs vm. values, P = 1.00). These
data indicate that both the primary tumour and its metastases are
sites of IL-6 production. In primary renal cell carcinoma similar
observations have been made (Blay et al, 1994).
Tumour growth might be influenced by IL-6 at different levels.
First, IL-6 might induce tumour cell proliferation. Second, IL-6
can stimulate VEGF expression in tumour cells, thus contributing
locally to a pro-angiogenic environment. Third, IL-6 induces
fibrinogen secretion by hepatocytes. As fibrinogen extravasation
kinetics are enhanced in tumours, IL-6 might in this manner
contribute to the formation of a fibrin matrix which is considered
to be important in stromal remodelling, a process intrinsically
related to angiogenesis. Fourth, circulating endothelial cell pro-
genitors (ECP) might contribute to intra-tumoural angiogenesis.
As these ECP originate from bone marrow, IL-6 might influence
their extravasation. As these ECP contain the VEGF-receptor,
enabling them to differentiate into endothelial cells, they may be
an additional stimulus for ongoing intra-tumoural angiogenesis.
Fifth, our previous results confirm the thrombopoietic properties
of IL-6 and suggest a role of IL-6 in the VEGF-regulation in
platelet precursors, the megakaryocytes. This might explain in part
the higher VEGF load in platelets from advanced cancer patients.
Platelets could subsequently adhere, aggregate and release this
higher VEGF load in tumours.
These observations might explain in part why patients with high
IL-6 levels, high platelet counts, high VEGF levels and, as demon-
strated by O’Byrne et al, a high VEGFPLT have worse prognosis.
The recent data provided by O’Byrne and colleagues provide
further evidence that platelets may be considered as mediators of
VEGF mediated endocrine modulation of tumour-related angio-
genesis.
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